APRIL 15, 2024

Biophytis files a patent application and strengthens its intellectual property in obesity Biophytis announces the filing of a patent application in the treatment of obesity, a new indication in which the Company has positioned itself with the announcement of its phase 2 OBA clinical trial. This new patent application, which is expected to be granted as soon as 2025, will strengthen BIO101’s (20-hydroxyecdysone) position in the treatment of obesity in combination with GLP-1 RAs. This new patent will extend the exclusivity period of BIO101 (20-hydroxyecdysone) in this indication until 2044. Stanislas Veillet, CEO de Biophytis comments: “This patent application completes

Read the press release »

APRIL 8, 2024

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 Biophytis announces that it is launching a new clinical development program named OBA, with BIO101 (20- hydroxyecdysone) as a potential treatment for obesity in combination with GLP-1 receptor agonists. Fullscreen Mode

Read the press release »

APRIL 8, 2024

Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis publishes its financial results for the year ended December 31, 2023, and provides an update on the progress of its various programmes. “In 2023, despite a particularly difficult financial environment for the biotech sector, we succeeded in pursuing the development of our clinical programmes, while securing the company’s financing until early 2025,” states Stanislas Veillet, CEO of Biophytis. “We were able to confirm the therapeutic value of BIO101 (20-hydroxyecdysone), our lead drug candidate, in the treatment of patients suffering from severe forms of COVID-19, opening

Read the press release »

APRIL 4, 2024

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 30% of the shareholders present or represented. The resolutions, which notably included a renewal of the usual financial delegations granted to the Company, were all approved. The results of the votes are available in the Investors / General Meetings section. Fullscreen Mode

Read the press release »

MARCH 22, 2024

Biophytis presented its phase 3 protocol in the treatment of sarcopenia Biophytis presented its phase 3 protocol aimed at demonstrating the potential of Ruvembri™ (20-hydroxyecdysone) in the treatment of sarcopenia at the International Conference on Frailty and Sarcopenia Research (ICFSR), held from March 20 to 22, 2024 in Albuquerque, NM, USA. The SARA-INT phase 2 study showed promising results on physical performance, with significant improvement in the 400 Meter Walking Test, reaching 0.07 m/s in the Full Analysis Set population and 0.09 m/s in the Per Protocol population. This outcome was replicated in pre-defined sub-populations at higher risk of mobility

Read the press release »

MARCH 18, 2024

Combined General Meeting of April 2, 2024 Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, will hold its Combined General Meeting (CGM) on April 2, 2024 at 2pm at Sorbonne Université- 4 Place Jussieu, 75005 Paris. The notice of meeting, including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des Annonces Légales Obligatoires (BALO)

Read the press release »

MARCH 15, 2024

Biophytis announces the implementation of a reverse stock split of its ordinary shares traded on Euronext Growth Biophytis announces that it has decided to implement a reverse stock split, with effect from April 2 2024, on the basis of 1 new share for every 400 held. Fullscreen Mode

Read the press release »

MARCH 12, 2024

Biophytis announces its participation in several events in Europe and the United States over the coming months Biophytis outcomes for patients suffering from age-related diseases, has announced its participation in several conferences until the end of the first half of 2024. Annual scientific conference on sarcopenia Biophytis management will take part in the 14th International Conference on Frailty and Sarcopenia Research, which brings together doctors and researchers specializing in sarcopenia and will be held in Albuquerque from 20 to 22 March 2024. The International Conference on Frailty & Sarcopenia Research is the major international scientific event on sarcopenia, bringing together

Read the press release »

MARCH 8, 2024

Biophytis presented the potential of Ruvembri™ in the treatment of Duchenne Muscular Dystrophy Biophytis presented the results of its recent clinical trials with Ruvembri™ at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held from 3 to 6 March 2024 in Orlando, USA. Administered orally, Ruvembri™ activates the MAS receptor, stimulating respiratory and motor functions. The results of the SARA-INT (phase 2) and COVA (phase 3) clinical trials demonstrated the efficacy and safety of Ruvembri™, respectively in sarcopenic patients and those suffering from severe forms of COVID-19. The data collected on these two vulnerable populations confirm the potential of

Read the press release »

FEBRUARY 22, 2024

“Live healthier longer” – Publication of a book on the medicine and science of longevity Biophytis announces the publication of a book written by Stanislas Veillet, CEO and co- founder of the company, together with René Lafont, Professor Emeritus at Sorbonne University and co- founder of Biophytis, and Jean Mariani, Professor and Director of the Charles Foix Longevity Institute, on the theme of “Healthy aging“. The title of the book is “Healthy aging – medicine and science of longevity“, and it addresses key public health issues in the context of a rapidly aging world population. This issue highlights the lack

Read the press release »